IKNA has 36-month beta value of 0.36. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IKNA is 25.16M, and currently, short sellers hold a 4.97% ratio of that float. The average trading volume of IKNA on April 19, 2024 was 428.38K shares.
IKNA) stock’s latest price update
The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 1.19 when compared to last closing price of 1.26. Despite this, the company has experienced a -4.14% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-10 that BOSTON, April 10, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event.
IKNA’s Market Performance
Ikena Oncology Inc (IKNA) has seen a -4.14% fall in stock performance for the week, with a -18.01% decline in the past month and a -16.12% plunge in the past quarter. The volatility ratio for the week is 7.50%, and the volatility levels for the past 30 days are at 7.97% for IKNA. The simple moving average for the past 20 days is -5.76% for IKNA’s stock, with a -56.92% simple moving average for the past 200 days.
Analysts’ Opinion of IKNA
Many brokerage firms have already submitted their reports for IKNA stocks, with Wedbush repeating the rating for IKNA by listing it as a “Outperform.” The predicted price for IKNA in the upcoming period, according to Wedbush is $11 based on the research report published on September 22, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IKNA reach a price target of $18. The rating they have provided for IKNA stocks is “Buy” according to the report published on May 04th, 2023.
H.C. Wainwright gave a rating of “Buy” to IKNA, setting the target price at $25 in the report published on December 23rd of the previous year.
IKNA Trading at -9.40% from the 50-Day Moving Average
After a stumble in the market that brought IKNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.31% of loss for the given period.
Volatility was left at 7.97%, however, over the last 30 days, the volatility rate increased by 7.50%, as shares sank -15.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.29% lower at present.
During the last 5 trading sessions, IKNA fell by -4.51%, which changed the moving average for the period of 200-days by -80.09% in comparison to the 20-day moving average, which settled at $1.3415. In addition, Ikena Oncology Inc saw -35.28% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IKNA
Current profitability levels for the company are sitting at:
- -8.23 for the present operating margin
- 0.81 for the gross margin
The net margin for Ikena Oncology Inc stands at -7.3. The total capital return value is set at -0.42. Equity return is now at value -43.04, with -37.42 for asset returns.
Based on Ikena Oncology Inc (IKNA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -7.43. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 58.19.
Currently, EBITDA for the company is -74.4 million with net debt to EBITDA at 1.44. When we switch over and look at the enterprise to sales, we see a ratio of -5.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.58.
Conclusion
To put it simply, Ikena Oncology Inc (IKNA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
